Dacomitinib - Pfizer

Drug Profile

Dacomitinib - Pfizer

Alternative Names: Dacomitinib; PF-00299804; PF-299; PF-299804; PF-804; VIZIMPRO

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Fondazione IRCCS Istituto Nazionale dei Tumori; Netherlands Cancer Institute; Pfizer; Seoul National University Hospital; SFJ Pharmaceuticals; University Health Network; University of California, San Diego
  • Class Amides; Aniline compounds; Antineoplastics; Piperidines; Quinazolinones; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Non-small cell lung cancer
  • Phase II Squamous cell cancer
  • Discontinued Brain metastases; Gastric cancer; Glioblastoma; Head and neck cancer; Orofacial cancer; Solid tumours

Most Recent Events

  • 04 Oct 2018 Discontinued - Phase-I for Head and neck cancer (Combination therapy, First-line therapy) in Canada (PO)
  • 04 Oct 2018 Discontinued - Phase-I for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Australia and USA (PO) (Pfizer pipeline, October 2018)
  • 04 Oct 2018 Discontinued - Phase-I for Non-small cell lung cancer (Neoadjuvant therapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top